This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): DX-88 (Intravenous), CB-500,929
DX-88 inhibits the protein kallikrein, a molecule involved in blood vessel responses to various stimuli. It plays a role in initiating a cascade of molecular events leading to increased vascular permeability, smooth muscle contraction, vasodilation, and pain.
Deal Structure: In June 2003, Dyax and Genzyme entered into a collaboration for the development of DX-88. Dyax and Genzyme are developing DX-88 for HAE in a 50/50 collaboration -- the two companies are each responsible for 50% of ongoing costs incurred in connection with the development and commercialization of DX-88 for HAE and each will be entitled to receive approximately 50% of any profits realized as a result. Dyax receives potential milestone payments from Genzyme in connection with the development of DX-88. Milestone payments are due upon dosing the first patient in a pivotal clinical trial of DX-88 for HAE, for the first FDA-approved product derived from DX-88, and for additional therapeutic indications developed under the collaboration.
In February 2007, Dyax reached a mutual agreement with Genzyme to terminate their joint venture for the development and commercialization of DX-88 for HAE. The termination agreement stipulates that Dyax will receive all the assets of the joint venture,...See full deal structure in Biomedtracker
Partners: Shire Pharmaceuticals Group PLC
Additional information available to subscribers only: